Sunday, April 21, 2024
Advertisement
  1. You Are At:
  2. News
  3. India
  4. COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella

COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella

COVID-19 vaccine: iNCOVACC, the world's first intranasal COVID-19 vaccine, was launched on January 26 (Thursday). The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments.

Sheenu Sharma Edited By: Sheenu Sharma New Delhi Updated on: February 05, 2023 18:29 IST
COVID 19 vaccine, iNCOVACC, intranasal covid vaccine, intranasal vaccine, COVID 19 vaccine, COVID va
Image Source : BHARAT BIOTECH (TWITTER). COVID-19: 3 lakh doses of intranasal vaccine iNCOVACC sent to hospitals, says Bharat Biotech's Krishna Ella.

COVID-19 vaccine: Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday (February 5).

He was speaking on the sidelines of an event at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.

iNCOVACC, the world's first intranasal COVID-19 vaccine, was launched on January 26 (Thursday). The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments.

"We dispatched three lakh doses of the world's first intranasal COVID-19 vaccine to some hospitals two days ago," Ella said.

On whether Bharat Biotech is looking at exporting the vaccine, he said some countries and international agencies are approaching the company for the intra-nasal vaccine. iNCOVACC is also the world's first intranasal COVID-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose for adults.

Health Centre by Bharat Biotech: 

Ella said the UW-Madison One Health Centre in Bengaluru is expected to be operational by the end of 2023.

It will advance the development and production of new vaccines for India. Furthermore, the partnership will enable collaboration across disciplines and geographic boundaries, provide Indian students and researchers access to UW expertise and training, and build research capacity in India, he said.

"Both Ella Foundation and UW-Madison GHI share a common vision to advance innovation in science, research, and knowledge sharing. Establishing the UW-Madison Global One Health Centre holds great significance as it will advance global health through research, education, and community engagement by facilitating student, faculty exchanges, research and education," he added.

UW-Madison GHI director Jorge Osorio said, "We are energised by the opportunity to partner with the Ella Foundation to bring UW knowledge and expertise to expand innovative and impactful health initiatives outside Wisconsin to India."

The India One Health Centre joins a global network that includes Africa and Latin America and will open new opportunities for research, education, and provide actionable outcomes to benefit humans, animals, and ecosystems that advance equitable and sustainable health across India and the world.

(With PTI inputs) 

ALSO READ: What is nasal vaccine - iNCOVACC? All you need to know

ALSO READ: COVID-19: Mansukh Mandaviya launches world's 1st Made-in-India nasal vaccine iNCOVACC

Advertisement

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from India

Advertisement
Advertisement
Advertisement
Advertisement